The market capitalization of China Shineway surpassed HK$10 billion and ranked as the largest Hong Kong listed pharmaceutical manufacturer in term of market capitalization China Shineway was named as a Hong Kong Outstanding Enterprise 2009. China Shineway received invention on "a compound for the treatment of mammary hyperplasia and its extraction and preparation methods" China Shineway obtained regulatory approval for the construction of Chinese Medicine Injection Engineering & Research Center from Hebei Province Qing Kai Ling Injection and Huo Xiang Zheng Qi Soft Capsule produced by China Shineway are listed as recommended medicines in the "Traditional Chinese Medicine Guide on Children A(H1N1) Influenza Prevention and Treatment" The Vietnamese Ministry of Health granted medicine permit to Shu Xue Ning Injection of China Shineway   Pediatric Qing Fei Hua Tan Granule, Qing Kai Ling Injection, Qing Kai Ling Soft Capsule, Coryza Soft Capsule and Liyan Jiedu Granule of China Shineway are included in the recommended list of "Hebei Province Chinese Medicine Prevention and Treatment on A(H1-N1) Influenza"   China Shineway commenced re-evaluation work on Shen Mei Injection   China Shineway received two invention patents in the area of treating kidney illness China Shineway was honored as a "Top 100 Growth Enterprise" in China   30 products of China Shineway are included in the "Essential Drug List"   Two quality control units of China Shineway received national honors of outstanding quality control of Pharmaceutical Industry   China Shineway is named as one of “Top 100 Privately-Owned Enterprises of Hebei Province” again Liyan Jiedu Granules, Pediatric Qing Fei Hua Tan Granule and Shujin Tongluo Granule received medicine licenses from the Health Sciences Authority of Singapore China Shineway received invention patent from the State Intellectual Property Office on medical application of curcuma longa extract to prevent or delay chronic renal failure   China Shineway commenced construction & "Modern Chinese Medicine Industrial Park" Qing Kai Ling Injection and Huo Xiang Zheng Qi Soft Capsule of China Shineway are recommended by the Ministry of Health for treatment of A(H1-N1) influenza China Shineway is honored as one of the “Top 20 Most Competitive Enterprises in the Pharmaceutical Industry of China” Shineway Pharmaceutical Co., Limited and Hebei Shineway Pharmaceutical Co., Limited were both assessed as high-tech enterprises   China Shineway is named as “iPower 500 Enterprises of China”   China Shineway is honored as an “2008 Innovative Small and Medium Size Enterprise of Hebei Province” China Shineway received GMP certificate from the Republic of Sudan   The Intermediate People’s Court of Shijiazhuang, Hebei Province, has confirmed its statutory recognition of China Shineway’s “Wu Fu” trademark as China Famous Trademark The British Standard Institute (BSI) renewed China Shineway’s certificates in Quality Management System (ISO9001), Environment Management System (ISO9001) and Occupational Health and Safety Management System (OHSAS18001)   Lian Shen Tong Lin Granule and Qi Huang Tong Mi Soft Capsule received new medicine certificates and production permits from the State Food and Drug Administration China Shineway is named as one of the “Enterprises with Upmost Corporate Social Responsibilities” from the Hebei Province, and Mr. Li Zhenjiang, our Chairman and President, is named as a “Top 10 Outstanding Individual of Corporate Social Responsibilities”